Skip to main content

Table 1 Demographics and clinical characteristics of patients in the training and validation cohort

From: A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection

Characteristic Training cohort Validation cohort P value
n = (145) n = (56)
No. (%) No. (%)
Gender    0.811
 Male 109 (75.2%) 43 (76.8%)  
 Female 36 (24.8%) 13 (23.2%)  
Age (years)    0.431
 ≤ 40 15 (10.3%) 8 (14.3%)  
 > 40 130 (89.7%) 48(85.7%)  
Family history    0.898
 Yes 35 (24.1%) 14 (25.0%)  
 No 110 (75.9%) 42 (75.0%)  
Smoking behavior    0.819
 Yes 88 (60.7%) 33 (58.9%)  
 No 57 (39.3%) 23 (41.1%)  
BMI (kg/m2)    0.630
 ≤ 22.3 80 (55.2%) 33 (58.9%)  
 > 22.3 65 (44.8%) 23 (41.1%)  
TNM stagea    0.846
 I 34 (23.4%) 11 (19.6%)  
 II 14 (9.7%) 5 (8.9%)  
 III 50 (34.5%) 23 (41.1%)  
 IV 47 (32.4%) 17 (30.4%)  
Size (cm)b    0.911
 ≤ 4.0 79 (54.5%) 31 (55.4%)  
 > 4.0 66 (45.5%) 25 (44.6%)  
Treatment    0.648
 Sur 31 (21.4%) 13 (23.2%)  
 Sur and Rad/Che 47 (32.4%) 18 (32.1%)  
 Rad/Che 54 (37.2%) 17 (30.4%)  
 Other 13 (9.0%) 8 (14.3%)  
WBC (10 9/L)    0.560
 ≤ 10.8 125 (86.2%) 50 (89.3%)  
 > 10.8 20 (13.8%) 6 (10.7%)  
Neutrophils (109/L)    
 ≤ 8.1 128 (88.3%) 51 (91.1%) 0.569
 > 8.1 17 (11.7%) 5 (8.9%)  
Lymphocyte (109/L)    
 ≤ 1.74 40 (27.6%) 17 (30.4%) 0.696
 > 1.74 105 (72.4%) 39 (69.6%)  
Platelet (109/L)    0.245
 ≤ 163.0 22 (15.2%) 5 (8.9%)  
 > 163.0 123 (84.8%) 51 (91.1%)  
NLR    0.521
 ≤ 2.7 90 (62.1%) 32 (57.1%)  
 > 2.7 55 (37.9%) 24 (42.9%)  
PLR    0.043
 ≤ 108.6 64 (44.1%) 16 (28.6%)  
 > 108.6 81 (55.9%) 40 (71.4%)  
HBsAb    0.107
 Negative 145 (100.0%) 55 (98.2%)  
 Positive 0 (0.0%) 1 (1.8%)  
HBeAg    0.026
 Negative 142 (97.9%) 51 (91.1%)  
 Positive 3 (2.1%) 5 (8.9%)  
HBeAb    0.016
 Negative 8 (5.5%) 9 (16.1%)  
 Positive 137 (94.5%) 47 (83.9%)  
HBcAb    0.022
 Negative 0 (0.0%) 2 (3.6%)  
 Positive 145 (100.0%) 54 (96.4%)  
ALB (g/L)    0.035
 ≤ 42.5 91 (62.8%) 26 (46.4%)  
 > 42.5 54 (37.2%) 30 (53.6%)  
ALT (U/L)    0.260
 ≤ 13.7 26 (17.9%) 14 (25.0%)  
 > 13.7 119 (82.1%) 42 (75.0%)  
AST (U/L)    0.370
 ≤ 32.2 124 (85.5%) 45 (80.4%)  
 > 32.2 21 (14.5%) 11 (19.6%)  
SLR    0.987
 ≤ 1.5 127 (87.6%) 49 (87.5%)  
 > 1.5 18 (12.4%) 7 (12.5%)  
ALP (U/L)    0.931
 ≤ 69.6 56 (38.6%) 22 (39.3%)  
 > 69.6 89 (61.4%) 34 (60.7%)  
APOA (g/L)    0.425
 ≤ 1.2 79 (54.5%) 27 (48.2%)  
 > 1.2 66 (45.5%) 29 (51.8%)  
APOB (g/L)    0.315
 ≤ 1.0 101 (69.7%) 43 (76.9%)  
 > 1.0 44 (30.3%) 13 (23.2%)  
ABR    0.057
 ≤ 0.8 14 (9.7%) 1 (1.8%)  
 > 0.8 131 (90.3%) 55 (98.2%)  
CRP (mg/L)    0.443
 ≤ 6.2 82 (56.6%) 35 (62.5%)  
 > 6.2 63 (43.6%) 21 (37.5%)  
CAR    0.278
 ≤ 0.16 81 (17.9%) 36 (64.3%)  
 > 0.16 64 (44.1%) 20 (35.7%)  
LDH (U/L)    0.755
 ≤ 230.3 119 (82.1%) 47 (83.9%)  
 > 230.3 26 (17.9%) 9 (16.1%)  
GGT (U/L)    0.731
 ≤ 44.2 116 (80.0%) 46 (82.1%)  
 > 44.2 29 (20.0%) 10 (17.9%)  
TBIL (umol/L)    0.652
 ≤ 15.4 115 (79.3%) 46 (82.1%)  
 > 15.4 30 (20.7%) 10 (17.9%)  
DBIL (umol/L)    0.813
 ≤ 3.0 57 (39.3%) 21 (37.5%)  
 > 3.0 88 (60.7%) 35 (62.5%)  
PNI    0.084
 ≤ 48.1 34 (23.4%) 7 (12.5%)  
 > 48.1 111 (76.6%) 49 (87.5%)  
PI    0.521
 0 92 (63.4%) 40 (71.4%)  
 1 39 (26.9%) 11 (19.7%)  
 2 14 (9.7%) 5 (8.9%)  
GPS    0.456
 0 93 (64.1%) 41 (73.2%)  
 1 46 (31.7%) 13 (23.2%)  
 2 6 (4.1%) 2 (3.6%)  
  1. BMI body mass index, TNM tumor node metastasis stage, Sur surgery; Rad: radiotherapy, Che chemotherapy, WBC white blood cell, NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, ALB albumin, ALT alanine transaminase, AST aspartate aminotransferase, SLR AST/ALT ratio, ALP alkaline phosphatase, APOA apolipoprotein AI, APOB apolipoprotein B, ABR APOA/APOB ratio, CRP C-reactive protein, CAR C-reactive protein/albumin ratio, LDH lactic dehydrogenase, GGT glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, PNI prognostic nutritional index, PI prognostic index, GPS Glasgow prognostic score
  2. aTNM stage was classified according to the AJCC 7th TNM staging system
  3. bThe tumor maximum diameter